Background: In 2020, melanoma exhibited the 5th highest incidence rate of all cancers in the US. While metastatic melanoma constitutes only 4% of new melanoma cases, the 5-year survival rate of metastatic melanoma is 27% [1]. Immune Checkpoint Inhibitors (ICIs) were the first drugs to significantly improve the 5-year survival of late-stage melanoma patients; these […]